Linical (2183.T)

Executive Summary

Linical is a global Contract Research Organization (CRO) headquartered in Tokyo, with a strong presence in the United States and other regions. Founded in 2002, the company provides comprehensive clinical development services across all phases, with specialized expertise in oncology, neuroscience, and immunology. Linical emphasizes a personalized, quality-centric partnership model to help biopharmaceutical clients accelerate drug development, from early-phase research to large-scale global studies. The company is publicly traded on the Tokyo Stock Exchange under ticker 2183.T, with a current valuation of approximately $5.6 billion. As a private company with a public listing, Linical benefits from both operational flexibility and access to capital markets, positioning it well for sustained growth in the competitive CRO sector. Its award-winning reputation and focus on high-therapeutic areas align with industry trends toward precision medicine and complex clinical trials.